OPERATION OLIGO CURE (OOC) was created raise awareness about for the rare brain tumor- Oligodendrogliomas. Oligodendrogliomas impact thousands of people worldwide.

OOC is currently supporting grants for the following projects:

  • Heidelberg: Epigenome Re-programming
    Epigenetics regulate gene expression and play an important role in cancer development.  IDH1 mutated Oligo (≈75% of Oligos) have been shown to have global hypermethylation and other abnormalities in the epigenome.  This research effort will evaluate the impact—and identify molecular determinants of response—of currently available inhibitors on IDH1mt Oligos, both in the lab and in the clinic (through a trial at Mass General). If this approach shows promise, it can move to clinical trial relatively quickly.
  • MD Anderson: Immune Profiling of Oligos
    Immunotherapy has become the area of greatest focus and progress in cancer research. However, little is currently known about the immune modulators (i.e. therapeutic targets) in Oligo.  This research will identify these targets and test existing inhibitors against our disease.  This is crucial information that will help point us to the best options for future clinical trials with existing therapies.
  • ICM, Paris: Development of IDH1 and CIC Mutated Mouse Model
    Genetically Engineered Mouse Models (GEMM) are required for preclinical testing of most immunotherapies.  This is collaboration between two researchers that have developed GEMMs with one of these keys mutations.  The aim of this project is to create a mouse model that incorporates both IDH1 and CIC which would make it much more representative of oligodendroglioma that existing models.  This GEMM could be the key to expanding preclinical immunotherapy work on Oligos and providing a more predictive model.
  • Yale:  Targeting IDH1mt Oligo with PARP and DNA Damaging Agents
    PARP inhibitors have recently been shown in the lab to reverse one of the key impacts of the IDH1 mutation in gliomas.  These inhibitors can not only kill glioma cells but can make other agents (chemotherapy) more effective.  This research will test the impact of a PARP inhibitor which is in development (and gets through the blood brain barrier) against Oligo, both alone and in combination with other agents. If successful, the next step would be a clinical trial.
  • MD Anderson:  Targeting Key Pathways of CIC mt Oligo
    50%-70% of Oligos have the CIC mutation. The role of this mutation in Oligo development and progression is not well understood.  This research will determine the functional roles of key proteins / signaling pathways and evaluate the effectiveness of specific FDA-approved inhibitors. If successful, the next step would be a clinical trial.

Brain tumors are the second leading cause of cancer-related deaths in children under age 20

Brain tumors are the second leading cause of cancer-related deaths in males ages 20- 39

Brain tumors are the fifth leading cause of cancer-related deaths in females ages 20- 39

OLIGODENDROGLIOMA (oligo den dro glioma)

Glioma is the name of a group of tumors that arise from the supporting cells in the brain. Oligodendroglioma is a specific type of glioma also known as a brain tumor. They are soft, greyish-pink and frequently occur in the frontal or temporal lobe although, can be found anywhere within the cerebral

hemisphere of the brain. They can be classified as low grade or high grade. They are common among men and women in their 20s-40s, but can occur in children. Oligodendrogliomas represent 4% of all primary brain tumors.